B-cell acute lymphoblastic leukemia · 13 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Blinatumomab monotherapy Variant #05 | — | R 1 099 557 | 56d | — | ~7.7 mo | ~4 | ~R 3 380 118 PFS proxy · indirect | 2 |
Dasatinib and Blinatumomab Variant #01 | BCR::ABL1 | R 787 275 | 42d | — | — | ~5 | ~R 3 936 373 indirect | — |
HAM and Imatinib Variant #01 | BCR::ABL1 | R 30 871 | 4d | — | — | ~1 | ~R 30 871 indirect | — |
International ALL Trial consolidation Variant #01 | — | R 18 689 | 56d | — | — | ~1 | ~R 18 689 indirect | — |
Nilotinib-based consolidation Variant #01 Partial | BCR::ABL1 | R 17 340 | — | — | — | ~4 | ~R 29 332 indirect | — |
Pediatric-like GRAALL consolidation Variant #01 Partial | — | R 8 802 | — | — | — | ~3 | ~R 26 407 indirect | — |
Linker regimen (consolidation) Variant #01 Partial | — | R 8 462 | 30d | — | — | ~4 | ~R 32 453 indirect | — |
Etoposide and TBI, then allo HSCT Variant #03 Partial | — | R 6 770 | — | — | — | ~1 | ~R 6 770 indirect | — |
Etoposide and TBI, then allo HSCT Variant #03 Partial | BCR::ABL1 | R 6 770 | — | — | — | ~1 | ~R 6 770 indirect | — |
AALL0232 consolidation Variant #01 Partial | — | R 6 249 | 50d | — | — | ~1 | ~R 6 249 indirect | — |
Mercaptopurine, Methotrexate, Vincristine Variant #02 | — | R 2 001 | 56d | — | — | ~2 | ~R 4 002 indirect | — |
Cyclophosphamide and TBI, then allo HSCT Variant #01 Partial | BCR::ABL1 | R 1 176 | — | — | — | ~1 | ~R 1 176 indirect | — |
Cyclophosphamide and TBI, then allo HSCT Variant #01 Partial | — | R 1 176 | — | — | — | ~1 | ~R 1 176 indirect | — |
13 of 13 regimens shown